Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) have earned an average recommendation of “Buy” from the seven brokerages that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $12.29.

Several equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Rani Therapeutics in a report on Tuesday, June 25th. Rodman & Renshaw assumed coverage on shares of Rani Therapeutics in a report on Thursday, June 13th. They issued a “buy” rating and a $10.00 price target for the company. BTIG Research boosted their price target on shares of Rani Therapeutics from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Finally, Maxim Group assumed coverage on shares of Rani Therapeutics in a report on Friday, June 14th. They issued a “buy” rating and a $15.00 price target for the company.

Rani Therapeutics Price Performance

NASDAQ:RANI opened at $2.93 on Tuesday. The company has a debt-to-equity ratio of 1.43, a current ratio of 3.09 and a quick ratio of 3.09. The firm has a market cap of $147.73 million, a price-to-earnings ratio of -2.27 and a beta of 0.16. The company has a 50 day moving average price of $4.04 and a 200-day moving average price of $4.23. Rani Therapeutics has a 1-year low of $1.82 and a 1-year high of $8.75.

Rani Therapeutics (NASDAQ:RANI) last posted its earnings results on Monday, May 6th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Equities research analysts forecast that Rani Therapeutics will post -1.05 EPS for the current year.

Institutional Investors Weigh In On Rani Therapeutics

A hedge fund recently raised its stake in Rani Therapeutics stock. Vanguard Group Inc. raised its holdings in shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) by 2.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 685,303 shares of the company’s stock after buying an additional 16,956 shares during the quarter. Vanguard Group Inc. owned about 1.37% of Rani Therapeutics worth $2,131,000 as of its most recent SEC filing. 30.19% of the stock is currently owned by institutional investors and hedge funds.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.